Peter Meldgaard

Assistant Professor

Aarhus University

Denmark

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Peter Meldgaard is an Assistant Professor at Aarhus University in Denmark. His research focuses on the development of diagnostic and treatment strategies for non-small cell lung cancer, including liquid biopsy techniques and the assessment of clinical outcomes in various lung cancer cohorts. Recent publications emphasize the validation of analytical methods for drug quantification and the investigation of patient risks and treatment efficacy within this field.

Articles (18)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (19)

Eric Santoni-Rugiu

Københavns Universitet

DENMARK

Peter Meldgaard

Research Interests

Explore related searches

Contact this professor

About

Articles (18)

Development and validation of an LC-MS/MS method for quantification of Osimertinib and its two metabolites AZ7550 and AZ5104 in human plasma including long-time storage

Risk of Venous Thromboembolism in Patients With Stage III and IV Non–Small-Cell Lung Cancer: Nationwide Descriptive Cohort Study

Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes

Integration of Cell-Free DNA End Motifs and Fragment Lengths Can Identify Active Genes in Liquid Biopsies

Improved overall survival for Stage III NSCLC patients treated with curative-intended therapy from 2010 to 2018–a cohort study in Denmark

Cell-free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients.

Circulating immune response proteins predict the outcome following disease progression of osimertinib treated epidermal growth factor receptor-positive non-small cell lung cancer patients.

Plasma Immune Proteins and Circulating Tumor DNA Predict the Clinical Outcome for Non-Small-Cell Lung Cancer Treated with an Immune Checkpoint Inhibitor

Can liquid biopsy dynamics stratify patients with small cell lung cancer?

Diagnostic Workup, Treatment Patterns, and Clinical Outcomes in Early-Stage IB–IIIA Non-Small-Cell Lung Cancer Patients in Denmark

Clinical outcomes of <i>ALK</i> + non-small cell lung cancer in Denmark

TDP1 and TOP1 as targets in anticancer treatment of NSCLC

Prognostic value of <i>KRAS</i> mutations, <i>TP53</i> mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy.

Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor-a Danish cohort study.

Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study.

Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.

EGFR transcription in non-small-cell lung cancer tumours can be revealed in ctDNA by cell-free chromatin immunoprecipitation (cfChIP).

Collaborators (19)

Eric Santoni-Rugiu

Christoffer Trier Månsson

Ann-Katrine Jakobsen

Mette Søgaard

Heidi Søgaard Christensen

Morten Ladekarl

Johanne Lade-Keller

Birgitte Bjørnhart

Boe Sorensen

Halla Skuladottir

Simone Stensgaard

Eva Holm Greibe

Andreas Carus

Erik Jakobsen

Simon Noble

Magnus Stougaard

Birgitta Ruth Knudsen

Anders L. Nielsen

Seppo W. Langer

Make your next move.